Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis.

Fiche publication

Date publication

février 2025

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier

Tous les auteurs :
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40052124

Résumé

This study describes treatment and retreatment patterns and outcomes in patients in France following nivolumab as a second-line or later (2L+) treatment in locally advanced or metastatic non-small cell lung cancer (LAM NSCLC).